BIOMARCARE
Biomarker for Cardiovascular Risk Assessment in Europe
| Coordinatore | UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Organization address
address: Martinistrasse 52 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Sito del progetto | http://www.biomarcare.eu/ |
| Totale costo | 7˙847˙985 € |
| EC contributo | 6˙000˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2011-two-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-10-01 - 2016-03-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Organization address
address: Martinistrasse 52 contact info |
DE (HAMBURG) | coordinator | 1˙255˙925.00 |
| 2 |
CAVADIS BV
Organization address
address: CATHARIJNESINGEL 52 contact info |
NL (UTRECHT) | participant | 867˙880.00 |
| 3 |
TERVEYDEN JA HYVINVOINNIN LAITOS
Organization address
address: MANNERHEIMINTIE 166 contact info |
FI (HELSINKI) | participant | 737˙440.00 |
| 4 |
FLEET BIOPROCESSING LIMITED
Organization address
address: PALE LANE PALE LANE FARM UNIT 6 contact info |
UK (HARTLEY WINTNEY HANTS) | participant | 576˙800.00 |
| 5 |
BIOCRATES LIFE SCIENCES AG
Organization address
address: EDUARD BODEM GASSE 8 1 STOCK contact info |
AT (Innsbruck) | participant | 372˙560.00 |
| 6 |
BIOCARTIS SA
Organization address
address: EPFL QUARTIER DE L INNOVATION - BUILDING G contact info |
CH (Lausanne) | participant | 291˙890.00 |
| 7 |
UNIVERSITAET ZU LUEBECK
Organization address
address: RATZEBURGER ALLEE 160 contact info |
DE (LUEBECK) | participant | 266˙700.00 |
| 8 |
RESEARCH NETWORK SERVICES LIMITED
Organization address
address: ST JOHN STREET 145-157 2ND FLOOR contact info |
UK (LONDON) | participant | 240˙000.00 |
| 9 |
"UMIT- PRIVATE UNIVERSITAT FUER GESUNDHEITSWISSENSCHAFTEN, MEDIZINISCHEINFORMATIK UND TECHNIK GMBH"
Organization address
address: EDUARD WALLNOEFER - ZENTRUM 1 contact info |
AT (HALL IN TIROL) | participant | 148˙080.00 |
| 10 |
MEDIZINISCHE HOCHSCHULE HANNOVER
Organization address
address: Carl-Neuberg-Strasse 1 contact info |
DE (HANNOVER) | participant | 110˙000.00 |
| 11 |
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Organization address
address: HEIDELBERGLAAN 100 contact info |
NL (UTRECHT) | participant | 105˙780.00 |
| 12 |
UNIVERSITETET I TROMSOE
Organization address
address: Hansine Hansens veg 14 contact info |
NO (TROMSO) | participant | 84˙084.00 |
| 13 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 81˙136.00 |
| 14 |
UNIVERSITA DEGLI STUDI DELL'INSUBRIA
Organization address
address: Via Ravasi 2 contact info |
IT (VARESE) | participant | 75˙239.00 |
| 15 |
TARTU ULIKOOL
Organization address
address: ULIKOOLI 18 contact info |
EE (TARTU) | participant | 74˙911.00 |
| 16 |
UNIVERSITY OF DUNDEE
Organization address
address: Nethergate contact info |
UK (DUNDEE) | participant | 68˙523.00 |
| 17 |
Nome Ente NON disponibile
Organization address
address: Domstrasse 11 contact info |
DE (GREIFSWALD) | participant | 67˙376.00 |
| 18 |
REGION HOVEDSTADEN
Organization address
address: KONGENS VAENGE 2 contact info |
DK (HILLEROD) | participant | 63˙773.00 |
| 19 |
UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ
Organization address
address: Langenbeckstrasse 1 contact info |
DE (Mainz) | participant | 57˙876.00 |
| 20 |
UNIVERSITA CATTOLICA DEL SACRO CUORE
Organization address
address: Largo Agostino Gemelli 1 contact info |
IT (MILANO) | participant | 56˙212.00 |
| 21 |
QUEEN'S UNIVERSITY BELFAST
Organization address
address: University Road contact info |
UK (BELFAST) | participant | 55˙910.00 |
| 22 |
INSTITUT PASTEUR DE LILLE FONDATION
Organization address
address: 1 Rue du professeur Calmette contact info |
FR (LILLE) | participant | 53˙945.00 |
| 23 |
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Organization address
address: Ingolstaedter Landstrasse 1 contact info |
DE (MUENCHEN) | participant | 52˙320.00 |
| 24 |
THE UNIVERSITY OF SYDNEY
Organization address
address: The University of Sydney contact info |
AU (SYDNEY) | participant | 51˙324.00 |
| 25 |
UMEA UNIVERSITET
Organization address
address: UNIVERSITETOMRADET contact info |
SE (UMEA) | participant | 48˙703.00 |
| 26 |
UNIVERSITAET ULM
Organization address
address: HELMHOLTZSTRASSE 16 contact info |
DE (ULM) | participant | 46˙418.00 |
| 27 |
UNIVERSITAETSSPITAL BASEL
Organization address
address: HEBELSTRASSE 32 contact info |
CH (BASEL) | participant | 39˙858.00 |
| 28 |
Nome Ente NON disponibile
Organization address
address: Av. Sant Antoni M. Claret 167 contact info |
ES (Barcelona) | participant | 30˙310.00 |
| 29 |
INSTITUTO NEUROLOGICO MEDITERRANEO- NEUROMED SRL
Organization address
address: VIA ATINENSE 18 contact info |
IT (POZZILLI IS) | participant | 19˙027.00 |
| 30 |
HAMILTON HEALTH SCIENCES CORPORATION
Organization address
address: 1280 MAIN STREET WEST contact info |
CA (HAMILTON) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Biomarkers are considered as tools to enhance cardiovascular risk estimation. However, the value of biomarkers on risk estimation beyond European risk scores, their comparative impact among different European regions and their role in the drive towards personalised medicine remains uncertain.
Based on harmonised and standardised European population cohorts we have built significant research collaboration, expertise and infrastructure in the EU. We will apply highly innovative SME-driven technologies and perform large-scale biomarker determination to assess the predictive value of existing and emerging biomarkers.
Selection of emerging biomarkers will be based on integrated cutting-edge quantitative proteomic, transcriptomic, metabolomic, and miRNomic datasets established by private and public consortium members that will be disclosed to this consortium. Existing biomarkers will be selected based on non-redundancy and their association with cardiovascular risk and phenotypes. After SME-guided development of innovative assay systems biomarkers will be tested and validated in a stepwise fashion among European populations in primary and secondary prevention. In addition to their impact on risk prediction, their association with lifestyle determinants and cardiovascular phenotypes assessed by ultrasound and MRI technique will be evaluated.
We will establish a BiomarCaRE panel which leads to improved disease prediction among different European populations. International collaborations with world-class clinical trial investigators will add data on the interaction of the BiomarCaRE panel with risk-lowering medication and lifestyle changes. The outcome of SME-driven technology development and clinical validation will undergo a medical technology assessment. The determination of cost-effectiveness will guide further clinical evaluation. These studies will reveal new methods of improved cardiovascular risk estimation and will open the path towards personalised medicine.'
Introduzione (Teaser)
Minimising the risk for cardiovascular disease is a great medical challenge. A European consortium proposes to identify biomarkers that could be used for disease risk prediction.
Descrizione progetto (Article)
The high incidence of cardiovascular disease constitutes a significant socioeconomic burden in developed countries. Extensive clinical research has led to the identification of biomarkers that could be utilised to predict the risk of heart disease. Whether these biomarkers are generic or applicable for precision medicine remains unclear.
To address this issue, the EU-funded http://www.biomarcare.eu/ (BIOMARCARE) (Biomarker for cardiovascular risk assessment in Europe) project is using European cohorts to perform large-scale biomarker determination. The outcome of the project should provide an overall picture on the predictive value of existing and emerging biomarkers.
The consortium employed cutting-edge quantitative technologies (proteomic, transcriptomic, metabolomic, and miRNA) to identify biomarkers based on their association with cardiovascular risk and disease phenotype. These biomarkers are validated among the European population and the long-term plan is to identify those that could be exploited for cardiovascular risk assessment.
Given the bulk of samples analysed, data harmonisation poses a significant challenge. BIOMARCARE partners have addressed this through a central data center that receives data from the different study sites and prepares them for analysis.
The outcome of the study will contribute towards a strategy for achieving individualised risk prediction of cardiovascular disease. The association of biomarkers with lifestyle choices and medication should help formulate health policies and potentially decrease cardiovascular disease incidence.
Apart from a healthcare perspective, the pharmaceutical industry would also be interested in a biomarker-based solution for increasing technical success of their new compounds. Using a biomarker-driven approach, they could obtain results much earlier in the drug development process, thus, significantly reducing R&D costs.